GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » Forward PE Ratio

ABL Diagnostics (XPAR:ABLD) Forward PE Ratio : 92.50 (As of May. 08, 2025)


View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics Forward PE Ratio?

ABL Diagnostics's Forward PE Ratio for today is 92.50.

ABL Diagnostics's PE Ratio without NRI for today is 792.86.

ABL Diagnostics's PE Ratio (TTM) for today is 462.50.


ABL Diagnostics Forward PE Ratio Historical Data

The historical data trend for ABL Diagnostics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics Forward PE Ratio Chart

ABL Diagnostics Annual Data
Trend
Forward PE Ratio

ABL Diagnostics Semi-Annual Data
Forward PE Ratio

Competitive Comparison of ABL Diagnostics's Forward PE Ratio

For the Health Information Services subindustry, ABL Diagnostics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Forward PE Ratio falls into.


;
;

ABL Diagnostics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


ABL Diagnostics  (XPAR:ABLD) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ABL Diagnostics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics Headlines